Shanghai Pharmaceuticals Confirms 2026 Sales and Procurement Framework with Yunnan Baiyao

Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has issued an announcement.

Shanghai Pharmaceuticals Holding Co., Ltd., a leading Chinese pharmaceutical manufacturer and distributor, focuses on the production and sale of a broad range of medicines and healthcare products for hospitals, pharmacies and other healthcare institutions in China and abroad. The company operates across the pharmaceutical value chain, leveraging its scale and network to support a diversified portfolio of drug products and related services.

The company has formally executed its 2026 Sales and Procurement Framework Agreement with Yunnan Baiyao, effective for the full year from 1 January to 31 December 2026, on terms consistent with those previously disclosed. The confirmation of this continuing connected transaction secures a defined framework for mutual sales and procurement between the two pharmaceutical groups for 2026, providing visibility over future business volumes and reinforcing Shanghai Pharmaceuticals’ commercial ties with a key sector partner, while the company states that all other previously announced information related to the arrangement remains unchanged.

The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.

More about Shanghai Pharmaceuticals Holding Co

Shanghai Pharmaceuticals Holding Co., Ltd. is a major Chinese pharmaceutical group engaged in the manufacture, distribution and sale of medicines and healthcare products, operating across both industrial and commercial pharmaceutical segments in domestic and international markets.

Average Trading Volume: 2,744,045

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$65.75B

See more data about 2607 stock on TipRanks’ Stock Analysis page.